Literature DB >> 2703383

NLP-1: a DNA intercalating hypoxic cell radiosensitizer and cytotoxin.

R Panicucci1, R Heal, K Laderoute, D Cowan, R A McClelland, A M Rauth.   

Abstract

The 2-nitroimidazole linked phenanthridine, NLP-1 (5-[3-(2-nitro-1-imidazoyl)-propyl]-phenanthridinium bromide), was synthesized with the rationale of targeting the nitroimidazole to DNA via the phenanthridine ring. The drug is soluble in aqueous solution (greater than 25 mM) and stable at room temperature. It binds to DNA with a binding constant 1/30 that of ethidium bromide. At a concentration of 0.5 mM, NLP-1 is 8 times more toxic to hypoxic than aerobic cells at 37 degrees C. This concentration is 40 times less than the concentration of misonidazole, a non-intercalating 2-nitroimidazole, required for the same degree of hypoxic cell toxicity. The toxicity of NLP-1 is reduced at least 10-fold at 0 degrees C. Its ability to radiosensitize hypoxic cells is similar to misonidazole at 0 degrees C. Thus the putative targeting of the 2-nitroimidazole, NLP-1, to DNA, via its phenanthridine group, enhances its hypoxic toxicity, but not its radiosensitizing ability under the present test conditions. NLP-1 represents a lead compound for intercalating 2-nitroimidazoles with selective toxicity for hypoxic cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2703383     DOI: 10.1016/0360-3016(89)90911-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

1.  Radioprotectant and radiosensitizer effects on sterility of gamma-irradiated bone.

Authors:  Seema A Kattaya; Ozan Akkus; James Slama
Journal:  Clin Orthop Relat Res       Date:  2008-05-17       Impact factor: 4.176

2.  DNA-targeted 2-nitroimidazoles: in vitro and in vivo studies.

Authors:  D S Cowan; J F Matejovic; R A McClelland; A M Rauth
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

3.  Radiosensitization and hypoxic cell toxicity of NLA-1 and NLA-2, two new bioreductive compounds.

Authors:  M V Papadopoulou; M W Epperly; D S Shields; W D Bloomer
Journal:  Jpn J Cancer Res       Date:  1992-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.